Psoriasisisachronicinflammatoryskindiseasecharacterizedbyepidermalhyperplasia(Acanthosis)withelongatedridgesandabnormaldifferentiationofepidermalkeratinocytes,dermalangiogenesis,abnormalaccumulationofpolymorphonuclearleukocytes,infiltrationofactivatedTcellsanddendriticcells,andincreasedcytokinelevels.MatTekhasdevelopedinvitromodelofPsoriasistoenablethestudyofthedisease,andtoscreentherapeuticcandidatesforsafetyandefficacy.Technology:MatTek’sdiseased3Dmodelofpsoriasisisproducedfromnormalhumanepidermalkeratinocytesandpsoriaticfibroblastsharvestedfrompsoriaticlesions.Thecellsareculturedonspeciallypreparedcellcultureinsertsusingserumfreemediumtoformamultilayered,highlydifferentiatedtissue.ThePsoriasistissuesmaintainapsoriaticphenotypeasevidencedbyincreasedbasalcellproliferation,expressionofpsoriasis-specificMarkersandelevatedreleaseofpsoriasis-specificcytokines.Morphologically,thetissuemodelcloselyparallelslesionalpsoriatichumantissues.Thismodelprovidesresearcherswithahumanrelevant,highlycontrolledinvitromodeltoassessthesafetyandefficacyofleadtherapeuticcompoundsandtostudyotherbasicpsoriasisBIOLOGyphenomena.Thepsoriasistissuemodelexhibitsapsoriaticphenotypeasevidencedbyincreasedexpressionofpsoriasis-associatedmarkersincludinghumanβ-defensin-2(HBD2),psoriasin,SKALP/elafin,keratinocytehyperproliferativecellsandproinflammatorycytokines/chemokinessuchasIL-6,IL-8,GM-CSF,andIP-10. Additionally,MatTek’sPsoriasismodelcanbeproducedfrom6differentdonorsallowingforthestudyoftherapeuticswhileaccountingforbiologicalvariABIlitybetweendonors.TheinvitroPsoriasismodelisresponsivetomarketedanti-psoriatictherapeuticsandisamenabletomodelskin–immunesysteminteractionswiththeexogenousadditionofsolubleimmunecellfactors. Applications:Anti-PsoriasisDrugScreeningThemodelprovidesresearcherswithauseful,invitromeanstoassessthepre-clinicalsafetyandefficacyofleadtherapeuticcompounds.PsoriasisApplicationNotePsoriasisDiseaseResearchThetissuemodelcloselyparallelslesionalpsoriatichumantissuesintermsofmorphologyandcytokineexpression.Thismodelprovidesresearcherswithauseful,invitromeanstostudypsoriasisbiologyphenomena.Searchourlibraryoftechnicalpapersformoreinformation.a[rel~="mtli_filesize81384kB"]:after {content:" (813.84 kB)"}TechSpecs:Tissue:Kit:ThePsoriasisTissueKit(SOR-300-FT)consistsof24tissues.Substrate:MilliporeMillicell™Cellcultureinsertused.Poresize=0.4μm,Diameter=0.8cm,Surfacearea=0.6cm2.Culture:Atairliquidinterface(apicaltissuesurfaceexposedtotheatmosphere).Histology:8-12celllayersplusstratumcorneum(basal,spinous,andgranularlayers).LotNumbers:Tissuelotsareproducedeveryotherweekandareassignedaspecificlotnumber.Aletterofthealphabetisappendedtotheendofthelotnumbertodifferentiatebetweenindividualkitswithinagivenlotoftissues.Alltissuekitswithinalotareidenticalinregardstocells,medium,handling,cultureconditions,etc.Shipment:At2-8°Conmedium-supplemented,agarosegelsin24-wellplates.Shipmentday:EveryotherMonday.Delivery:TuesdaymorningviaFedExpriorityservice(US).OutsideUS:Tuesday-Thursdaydependingonlocation.Shelflife:Includingtimeintransit,tissuesmaybestoredintheiroriginalpackageat2-8°Cforupto4dayspriortouse.Thebestreproducibilitywillbeobtainediftissuesareusedconsistentlyonthesameday,e.g.Tuesdayafternoonorfollowingovernightstorageat2-8°C(Wednesdaymorning).Extendedstorageperiodsarenotrecommended.Lengthofexperiments:Culturescanbecontinuedforupto2weekswithgoodretentionofnormalepidermalmorphology.Culturesmustbefedeveryotherdaywith5.0mlofSOR-300-FT-MMmedium.Culturestands(MatTekpart#:MEL-STND)arerequiredforexperimentsinexcessof24hrs.Alternativetissues:SOR-300-FT-ABF:Antibiotic-freetissue.Forlast3daysofculture,gentamicinisomittedfromculturemedium.CustomeralsoreceivesSOR-300-FT-MM-AFABmedium.SOR-300-FT-AFF:Anti-fungal-freetissue.Forlast3daysofculture,Amphotericinisomittedfromculturemedium.CustomeralsoreceivesSOR-300-FT-MM-AFABmedium.SOR-300-FT-AFAB:Antibiotic,anti-fungal-freetissue.Forlast3daysofculture,gentamicinandAmphotericinareomittedfromculturemedium.CustomeralsoreceivesSOR-300-FT-MM-AFABmedium.SOR-300-FT-CTR:NormalhealthycontroltissueforpsoriasisexperimentsCells:Type:Normalhumanepidermalkeratinocytes(NHEK);psoriatichumandermalfibroblasts(PHDF).Derivedfrom:Neonatal-foreskintissue(NHEK);adultpsoriaticexplants(PHDF)Screenedfor:HIV,Hepatitis-B,Hepatitis-C,andmycoplasma.Medium:Basemedium:Dulbecco’sModifiedEagle’sMedium(DMEM).Growthfactors/hormones:Epidermalgrowthfactor,insulin,hydrocortisoneandotherproprietarystimulatorsofepidermaldifferentiation.Serum:None.Antibiotics:Gentamicin5µg/ml(10%ofthenormalgentamicinlevel).Anti-fungalagent:AmphotericinB0.25µg/ml.pHIndicator:Phenolred.Otheradditives:Lipidprecursorsusedtoenhanceepidermalbarrierformation(proprietary).Alternatives:Phenolred-free(SOR-300-FT-PRF),antibiotic-free(SOR-300-FT-ABF),anti-fungal-free(SOR-300-FT-AFF),orhydrocortisone-freemediumandtissue(SOR-300-FT-HCF)areavailable.Agentsareremoved3dayspriortoshipment.Assay/Maintenancemedium:SOR-300-FT-MMisusedforequilibrationoftissuesfollowingshipmentandformaintenanceoftheSOR-300-FTtissuesincultureduringexperiments.QualityControlandSterility:Visualinspection:Alltissuesarevisuallyinspectedandifphysicalimperfectionsarenoted,tissuesarerejectedforshipment.End-usetesting:Tissuesareexposedto1%TritonX-100for4,6,8and10hours.Thetimeofexposurerequiredtoreducethetissueviability(ET-50)usingtheMTTviabilityassayisdetermined(SeeMatTekPsoriasisTissueuseprotocol)foreachlotoftissue.ET-50’sgenerallyfallwithintherangeof6.0-12.0hours.ET-50’sincustomers’labmaydifferslightlyfromtheMatTekresults.Inaddition,qPCRdataforpsoriasisrelatedgeneswillbemonitored.Increasesof>5foldforpsoriasin,humanbeta-defensin-2andelafinareexpected.Sterility:Allmediausedthroughouttheproductionprocessischeckedforsterility.Maintenancemediumisincubatedwithandwithoutantibioticsfor1weekandcheckedforsterility.Theagarosegelfromthe24-wellplateusedforshippingisalsoincubatedfor1weekandcheckedforanysignofcontamination.Screeningforpathogens:AllcellsarescreenedandarenegativeforHIV,hepatitisBandhepatitisCusingPCR.However,noknowntestmethodcanoffercompleteassurancethatthecellsarepathogenfree.Thus,theseproductsandallhumanderivedproductsshouldbehandledatBSL-2levels(biosafetylevel2)orhigherasrecommendedintheCDC-NIHmanual,“Biosafetyinmicrobiologicalandbiomedicallaboratories,”1998.Forfurtherassistance,pleasecontactyoursiteSafetyOfficerorMatTektechnicalservice.Notificationoflotfailure:IfatissuelotfailsourQCorsterilitytesting,thecustomerwillbenotifiedandthetissueswillbereplacedwithoutchargewhenappropriate.BecauseourQCandsterilitytestingisdonepost-shipment,notificationwillbemadeassoonaspossIBLe(Undernormalcircumstances,ET-50failureswillbenotifiedbyThursday5pm;sterilityfailureswillbenotifiedwithin8daysofshipment).
MatTek公司是麻省理工学院两个化学工程教授于1985成立的科技公司。1991年,该公司利用其核心的聚合物表面改性技术进入新兴的组织工程领域,目前已成长为的组织工程技术公司,致力于生产创新性的3D重构人体组织模型,该模型相较于传统2D细胞模型具有更可靠的实验结果。其生产的重构皮肤,眼部和呼吸道组织模型已广泛应用于化妆品,化工,医药和家用产品等行业的毒理学监控(OECD,欧盟的指导方针)及毒理学研究。
MatTek公司的基于人体细胞的3D皮肤模型EpiDerm于1993年研发上市,立即获得巨大的成功。从此MatTek通过以下方式彻底改变了基于人体细胞的体外模型市场:(1)低成本(降低50-80%的成本);(2)通过发表质量控制标准(同时具备阳性和阴性对照)以确保可为行业及监管机构接受的高可重复性水平;(3)优化研究人员的实验结果。通过创造性使用非动物的体外测试,融合降低(直接/间接)成本的强大协同效应及显著提高的产品质量,MatTek极大的降低产品成本、提高实验室效率及高质量的高可重复性产品,减少实验动物的使用,具有无可超越的长期组织可重复性;3-D仿真结构;高度分化的组织模型;代谢和分裂活性;源于正常的人体细胞;培养、操作简便;无血清培养;可定量的客观检测;物美价廉的优点。因而使得MatTek人细胞来源的体外组织模型被包括美国、加拿大、欧洲、日本和东亚的众多跨国公司与研究机构采用。
目前MatTek公司的产品主要包括EpiDerm(皮肤模型)、MelanoDerm(黑色素模型)、EpiOcular(眼周表皮模型)、EpiAirway呼吸道上皮模型)、EpiDermFT (全厚的皮肤模型) 、EpiVaginal(阴道上皮模型)、EpiOral(口腔上皮模型)、 EpiGingivalTM(牙龈上皮模型)、Psoriasis tissue(牛皮癣组织模型)及树突细胞。